PDCD1 and neoplasm: With the availability of the double knock-in of human-PD-1 and PD-L1 C57/Bl6 mice and the corresponding human-PD-L1-expressing murine tumor cell lines, we tested the efficacy of the clinical molecule, KD033, in this transgenic murine model.